Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.

PubWeight™: 2.36‹?› | Rank: Top 2%

🔗 View Article (PMID 9521169)

Published in J Natl Cancer Inst on March 18, 1998

Authors

J Yoneda1, H Kuniyasu, M A Crispens, J E Price, C D Bucana, I J Fidler

Author Affiliations

1: Department of Cell Biology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Associated clinical trials:

Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818) | NCT02584478

Articles citing this

The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01

In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia (1999) 2.71

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol (2013) 2.69

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27

Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol (2002) 2.13

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07

Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol (2002) 1.96

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 1.93

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene (2003) 1.72

Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.71

Chemokines in health and disease. Exp Cell Res (2011) 1.69

Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev (2007) 1.63

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61

Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58

Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia (2001) 1.52

AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res (2010) 1.50

Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol (2001) 1.49

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther (2009) 1.47

CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res (2010) 1.44

Chemokines as mediators of angiogenesis. Thromb Haemost (2007) 1.40

Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol (1999) 1.34

Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer (2005) 1.34

Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (2008) 1.29

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29

Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol (2000) 1.26

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov (2013) 1.22

Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer (1999) 1.18

Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol (2003) 1.17

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol (2002) 1.16

The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci (2011) 1.15

Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res (2010) 1.14

Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res (2011) 1.14

EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther (2008) 1.13

Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila) (2008) 1.12

Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol (2011) 1.11

Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res (2010) 1.11

TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res (2011) 1.08

VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer (2005) 1.06

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res (2008) 1.04

Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs (2007) 1.03

A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol (2007) 1.03

Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res (2011) 1.03

Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol (1999) 1.03

CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting. World J Gastroenterol (2014) 1.02

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther (2010) 1.02

Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam (2011) 1.01

Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res (2011) 1.00

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99

Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia (2007) 0.95

An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Proc Natl Acad Sci U S A (2003) 0.94

Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed) (2011) 0.94

Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci (2013) 0.93

Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models. Front Oncol (2013) 0.93

The role of CXC chemokines and their receptors in the progression and treatment of tumors. J Mol Histol (2012) 0.92

Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol (2009) 0.92

Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia (2001) 0.90

Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neoplasia (2006) 0.88

Selection of more aggressive variants of the gI101A human breast cancer cell line: a model for analyzing the metastatic phenotype of breast cancer. Clin Exp Metastasis (2003) 0.86

Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study. Clin Exp Metastasis (2000) 0.85

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Onco Targets Ther (2014) 0.85

Hypoxic pre-conditioning increases the infiltration of endothelial cells into scaffolds for dermal regeneration pre-seeded with mesenchymal stem cells. Front Cell Dev Biol (2015) 0.83

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther (2015) 0.83

4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression. J Ovarian Res (2014) 0.83

Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia (2013) 0.82

Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J Neurosurg (2008) 0.81

Association between preeclampsia and the CXC chemokine family (Review). Exp Ther Med (2015) 0.80

Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today (2010) 0.80

Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo. Int J Mol Sci (2010) 0.80

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res (2015) 0.78

Normal and SV40 transfected human peritoneal mesothelial cells produce IL-6 and IL-8: implication for gynaecological disease. Clin Exp Immunol (2002) 0.78

Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase. J Oncol (2012) 0.78

Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer. World J Crit Care Med (2013) 0.78

Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model. Transl Oncol (2014) 0.78

Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clin Exp Metastasis (1999) 0.78

Doublet chemotherapy in the elderly patient with ovarian cancer. Oncologist (2012) 0.78

Necrotic cells influence migration and invasion of glioblastoma via NF-κB/AP-1-mediated IL-8 regulation. Sci Rep (2016) 0.78

Transcriptional regulation of chemokine expression in ovarian cancer. Biomolecules (2015) 0.77

AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget (2016) 0.76

Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf (2012) 0.75

The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer. Oncogene (2016) 0.75

The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis. Sci Rep (2016) 0.75

LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer (2016) 0.75

Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. Eur J Gynaecol Oncol (2013) 0.75

Relevant molecular markers and targets. Gynecol Oncol (2006) 0.75

Articles by these authors

Metastasis results from preexisting variant cells within a malignant tumor. Science (1977) 6.47

The pathogenesis of cancer metastasis. Nature (1980) 5.74

Selection of successive tumour lines for metastasis. Nat New Biol (1973) 5.03

Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst (1970) 4.88

Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res (1995) 4.84

Biological diversity in metastatic neoplasms: origins and implications. Science (1982) 3.95

Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res (1975) 3.59

Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res (1978) 3.54

Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci U S A (1980) 3.38

The biology of cancer invasion and metastasis. Adv Cancer Res (1978) 2.94

Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev (1999) 2.83

Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene (2001) 2.71

In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia (1999) 2.71

A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69

Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res (1988) 2.67

Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res (1996) 2.59

The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer (1973) 2.54

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res (2000) 2.43

Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev (1986) 2.42

In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res (1980) 2.40

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res (1999) 2.39

Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res (1991) 2.37

In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res (1988) 2.36

Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res (1986) 2.30

Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res (1994) 2.28

Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res (1978) 2.28

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res (1999) 2.26

Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell (1997) 2.16

Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res (1984) 2.13

Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst (1976) 2.09

A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst (1984) 2.08

Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res (1993) 2.07

Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg (1997) 2.01

Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst (1990) 2.00

Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res (1996) 2.00

Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst (1992) 2.00

Specificity of arrest, survival, and growth of selected metastatic variant cell lines. Cancer Res (1978) 1.99

Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res (2000) 1.98

Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res (1980) 1.97

Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis (1991) 1.95

Mekk3 is essential for early embryonic cardiovascular development. Nat Genet (2000) 1.95

A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett (1987) 1.94

Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res (1984) 1.88

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A (1995) 1.87

Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A (1981) 1.87

Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J (2001) 1.86

Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol (1995) 1.82

Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res (2001) 1.80

The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res (2001) 1.80

Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol (1998) 1.75

Angiogenesis and metastasis. Eur J Cancer (1996) 1.72

Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res (1995) 1.71

Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res (1991) 1.70

Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst (1996) 1.69

The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte system in vivo. J Immunol (1988) 1.63

Metastatic colonization potential of primary tumour cells in mice. Br J Cancer (1979) 1.62

In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice. Clin Exp Metastasis (1989) 1.62

Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer (2000) 1.58

Angiogenesis and breast cancer metastasis. Lancet (1995) 1.55

Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst (1997) 1.55

Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia (2001) 1.52

Evidence for the clonal origin of spontaneous metastases. Science (1982) 1.52

Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer (1992) 1.50

Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst (1980) 1.49

Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res (2000) 1.48

Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clin Exp Metastasis (1999) 1.47

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer (2001) 1.47

Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res (2000) 1.47

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer (2002) 1.47

Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res (1986) 1.47

Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res (1999) 1.45

Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci U S A (1981) 1.44

Tyrosine phosphorylation of mitogen-activated protein kinases is necessary for activation of murine macrophages by natural and synthetic bacterial products. J Exp Med (1993) 1.44

Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res (1976) 1.44

Direct correlation between DNA repair capacity and metastatic potential of K-1735 murine melanoma cells. J Invest Dermatol (1997) 1.44

Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res (1999) 1.43

Macrophages and metastasis--a biological approach to cancer therapy. Cancer Res (1985) 1.43

Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med (1998) 1.43

Specific chromosomal defects associated with metastatic potential in K-1735 melanoma clones. Involvement of chromosomes 4 and 14. Cancer Genet Cytogenet (1991) 1.41

EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer (2001) 1.41

Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res (1982) 1.40

Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst (1986) 1.38

Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst (1994) 1.37

Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med (1995) 1.37

Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst (1981) 1.37

Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res (2000) 1.36